Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence
- PMID: 21106545
- DOI: 10.1136/jcp.2010.075945
Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence
Abstract
Background: Barrett oesophagus (BO) occurs as a consequence of prolonged gastro-oesophageal reflux and it may precede the development of oesophageal adenocarcinoma.
Aims: The aim of this study was to accurately assess Cdx2 expression in the oesophageal metaplasia-dysplasia-adenocarcinoma sequence.
Method: The expression of the transcription factor Cdx2 in Barrett metaplasia, high-grade glandular dysplasia and adenocarcinoma was investigated using immunohistochemistry.
Results: The results confirmed previous immunohistochemistry and PCR-based investigations, indicating that Cdx2 was expressed by intestinal metaplasia in the oesophagus. In addition, upregulation followed by linear downregulation of Cdx2 expression through the oesophageal metaplasia-dysplasia-adenocarcinoma sequence was demonstrated for the first time.
Conclusion: Such downregulation of Cdx2 expression could be in keeping with a role as a tumour suppressor gene, but a simpler explanation would be downregulation of a differentiation marker.
Similar articles
-
Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.Histopathology. 2014 Mar;64(4):536-46. doi: 10.1111/his.12296. Epub 2013 Nov 23. Histopathology. 2014. PMID: 24117499
-
Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.Int J Exp Pathol. 2018 Feb;99(1):10-14. doi: 10.1111/iep.12260. Epub 2018 Feb 23. Int J Exp Pathol. 2018. PMID: 29473241 Free PMC article.
-
COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.Dig Liver Dis. 2007 Apr;39(4):305-11. doi: 10.1016/j.dld.2007.01.011. Epub 2007 Feb 16. Dig Liver Dis. 2007. PMID: 17307036
-
The role of Cdx2 in Barrett's metaplasia.Biochem Soc Trans. 2010 Apr;38(2):364-9. doi: 10.1042/BST0380364. Biochem Soc Trans. 2010. PMID: 20298184 Review.
-
[Mucosal biopsy diagnosis of Barrett's esophageal: an update].Zhonghua Bing Li Xue Za Zhi. 2010 Jul;39(7):497-500. Zhonghua Bing Li Xue Za Zhi. 2010. PMID: 21055188 Review. Chinese. No abstract available.
Cited by
-
[Barrett's esophagus. An update].Pathologe. 2012 Feb;33(1):5-16. doi: 10.1007/s00292-011-1541-0. Pathologe. 2012. PMID: 22293785 Review. German.
-
CDX2 protein expression compared to alcian blue staining in the evaluation of esophageal intestinal metaplasia.World J Gastroenterol. 2015 Mar 7;21(9):2770-6. doi: 10.3748/wjg.v21.i9.2770. World J Gastroenterol. 2015. PMID: 25759548 Free PMC article.
-
Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.Diagn Pathol. 2016 Feb 29;11:23. doi: 10.1186/s13000-016-0473-7. Diagn Pathol. 2016. PMID: 26926447 Free PMC article.
-
Does Bile Reflux Influence the Progression of Barrett's Esophagus to Adenocarcinoma? (Gastroenterology 2013;145:1300-1311).J Neurogastroenterol Motil. 2014 Jan;20(1):124-6. doi: 10.5056/jnm.2014.20.1.124. Epub 2013 Dec 30. J Neurogastroenterol Motil. 2014. PMID: 24466454 Free PMC article. No abstract available.
-
Development of a novel oncolytic adenovirus controlled by CDX2 promoter for esophageal adenocarcinoma therapy.J Gastroenterol. 2024 Nov;59(11):986-999. doi: 10.1007/s00535-024-02147-2. Epub 2024 Sep 4. J Gastroenterol. 2024. PMID: 39227437
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical